Abstracts

Vpr ENHANCES HIV REPLICATION BY INHIBITING T CELL PROLIFERATION

Background: The resting HIV reservoir is a major obstacle towards curing HIV+ people. The reservoir is composed of clonally expanded T cells that predominantly harbor defective proviruses. A few infected cells containing replication-competent provirus are responsible for rebound viremia after treatment interruption. It is known the Vpr protein inhibits proliferation in cell lines. However, the…

SEVERAL InSTI AFFECT IMMUNE CELL MITOCHONDRIA, PROLIFERATION, AND APOPTOSIS EX VIVO

Background: HIV integrase strand transfer inhibitors (InSTI) are popular among people living with HIV for their tolerability and low pill burden. However, compared to older antiretrovirals (ARVs), little is known about their mitochondrial toxicities. Dolutegravir has been associated with weight gain in adults, which may reflect changes in cellular metabolism regulated by mitochondria. Mitochondrial toxicity…

RESTORATION OF HUMORAL RESPONSE TO COVID-19 VACCINATION IN RITUXIMAB-TREATED PATIENTS

Background: Previous studies had demonstrated that patients with hematologic malignancies had suboptimal antibody response after receiving COVID-19 vaccines, especially among those having previously treated with anti-CD20 monoclonal antibodies. Methods: Adult patients with non-Hodgkin’s lymphoma or chronic lymphocytic leukemia (CLL) were enrolled before receiving the second dose of SARS-CoV-2 vaccine. Determinations of anti-SARS-CoV-2 spike and nucleocapsid…

CMV, SEX, AND COGNITION IN PEOPLE WITH HIV (PWH)

Background: Interactions between chronic co-infections, HIV persistence, and immune response have been implicated in persistent inflammation and cognitive disorders in people with HIV (PWH), but findings have been inconsistent. Most data are based on serology and have not examined sex effects. We aimed to assess the relationships among viral DNA, IgG, and cognition and whether…

REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19

Background: There is limited information on effectiveness of COVID-19 therapies in immunocompromised patients, who are at higher risk of hospitalizations, complications, and mortality due to COVID-19. We examined hospital all-cause mortality for early RDV use vs. no RDV use among immunocompromised COVID-19 patients across several distinct dominant variants of concern (VOC) periods: pre-Delta (Dec’20-Apr’21), Delta…

REMDESIVIR REDUCES MORTALITY IN HOSPITALIZED COVID-19 PATIENTS ACROSS VARIANT ERAS

Background: Clinical management of COVID-19 based on oxygenation requirements continues to change over time as variants of concern (VOC) evolve. We examine hospital all-cause mortality for early hospital RDV use vs. no RDV use across dominant VOC periods: pre-Delta (Dec’20-Apr’21), Delta (May-Nov’21) and Omicron (Dec’21-Apr’22). Methods: We examined adults with a primary discharge diagnosis of…

REMDESIVIR IS ASSOCIATED WITH REDUCED READMISSION AFTER COVID-19 HOSPITALIZATION

Background: There is limited data on the association between COVID-19 therapy and hospital readmissions, including during evolution of the pandemic over time. We examine all cause 30-day readmissions after a COVID-19 hospitalization among remdesivir (RDV)-treated vs non-RDV treated patients across different dominant variants of concern (VOC) periods: pre-Delta (May’20-Apr’21), Delta (May-Nov’21) and Omicron (Dec’21-Apr’22). Methods:…

A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV

Background: Post-integration HIV latency is the major hurdle for a cure. To counter HIV latency, it is important to develop a better understanding of the full range of host factors promoting latency. Their identification could suggest new strategies to achieve a functional cure. We recently developed a genetic screening strategy termed “Reiterative Enrichment and Authentication…